The weekly litigation news digest is live. Subscribe now

IP Verse

New Use - EP3626270

The patent EP3626270 was granted to Novartis on Oct 11, 2023. The application was filed on Aug 26, 2014 under application number EP19202854A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3626270

NOVARTIS
Application Number
EP19202854A
Filing Date
Aug 26, 2014
Status
Granted And Under Opposition
Sep 8, 2023
Publication Date
Oct 11, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Angiotensin Receptor Neprilysin Inhibitors (ARNIs) and combined ARBs with NEPi pro-drugs for the prevention or delay of cardiovascular mortality and hospitalization in heart failure patients. The ARNI/ARB combination therapy demonstrates significant mortality reduction in patients with reduced ejection fraction, a key population for heart failure treatment, compared to conventional ACE inhibitors. This dual-action approach combines the RAAS pathway's natural compensatory mechanisms with the NEP's N-terminal dipeptidyl peptidase-IV inhibitor properties, achieving sustained benefits beyond traditional treatments.

Patent Family

Patent Family

Patent Oppositions (17)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
ELPEN PHARMACEUTICALJul 11, 2024HASELTINE LAKE KEMPNERADMISSIBLE
GENERICS UKJul 11, 2024ELKINGTON AND FIFEADMISSIBLE
LANYON OPPOSITIONSJul 11, 2024PINSENT MASONSADMISSIBLE
ZENTIVA KSJul 11, 2024GREINERADMISSIBLE
BULLE DRJul 10, 2024KUTZENBERGER WOLFF & PARTNERADMISSIBLE
CAMULONJul 10, 2024REDDIE & GROSEADMISSIBLE
DR SCHONJul 10, 2024DR SCHONADMISSIBLE
POLPHARMAJul 10, 2024HAMM & WITTKOPPADMISSIBLE
SYNTHONJul 10, 2024HOFFMANN EITLEADMISSIBLE
TEVA PHARMACEUTICALSJul 10, 2024D YOUNGADMISSIBLE
WUESTHOFF & WUESTHOFFJul 10, 2024SONNENHAUSERADMISSIBLE
HOFFMANN EITLEJul 9, 2024HOFFMANN EITLEWITHDRAWN
EGISJul 8, 2024STOLMAR & PARTNERADMISSIBLE
HAMM & WITTKOPPJul 5, 2024HAMM & WITTKOPPADMISSIBLE
HAMM & WITTKOPPJul 5, 2024HAMM & WITTKOPPWITHDRAWN
BETAPHARM ARZNEIMITTELJul 2, 2024HAMM & WITTKOPPADMISSIBLE
ALFRED E TIEFENBACHERJun 25, 2024HAMM & WITTKOPPADMISSIBLE

Patent Citations (13) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0443983
DESCRIPTIONUS5217996
DESCRIPTIONUS5399578
DESCRIPTIONWO03059345
DESCRIPTIONWO2007056546
DESCRIPTIONWO2009061713
DESCRIPTIONWO2014029848
OPPOSITIONUS2013158088
OPPOSITIONWO03059345
OPPOSITIONWO2007056546
OPPOSITIONWO2015028941
SEARCHUS2013158088
SEARCHWO2007056546

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents